The approval was obtained by Grand Pharmaceutical Group Limited (“Grand Pharma”), Tarsus’ exclusive partner for the development and commercialization of TP-03 for the treatment of Demodex blepharitis ...

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments. This is a video synopsis/summary of an Insights ...

This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye ...

Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) said it will receive a $15 million milestone payment after China’s National Medical Products Administration approved TP-03 (lotilaner ophthalmic solution) ...

(Yicai) March 23 -- Shares in Grand Pharma tumbled today despite the Chinese drugmaker being given the greenlight to take its first-in-class eye treatment for demodex blepharitis, a chronic eyelid ...

Neda Shamie, MD, summarizes the prevalence and clinical manifestations of Demodex Blepharitis. This is a video synopsis/summary of an Insights involving Neda Shamie, MD. Until recently, there were no ...

Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...

IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment ...

TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated IRVINE, Calif., Dec.